Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

  • Technology appraisal guidance
  • TA1156
  • Published: 
The second appraisal committee meeting has been scheduled for 20 November 2025.

This page was last updated: